The present invention relates to an interferon gamma (IFN-γ) inhibitor, and Alzheimer's disease, prion disease, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, grape, which can be treated or controlled by inhibition of IFN-γ production. It relates to its use in the treatment or control of diseases such as membrane inflammation, autoimmune skin disease, psoriasis, Sjogren's syndrome, Crohn's disease, and type I diabetes. The compound is a compound of formula 1, formula 2, or formula 3, or a solvate, tautomer, or pharmaceutically acceptable salt thereof, in (I), (II), (III), A is i. 5 each independently selected from a halogen atom, a haloalkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and a haloalkoxy group having 1 to 4 carbon atoms A phenyl ring substituted with the following substituents, ii. Each independently a halogen atom, an alkyl group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and 1 to 4 carbons A thiophene ring optionally substituted with up to 3 substituents selected from haloalkoxy groups having atoms, and iii. C (R d ) 3 groups, wherein R d is each independently hydrogen, an alkyl group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 4 carbon atoms, 1 to 4 An alkoxy group having a carbon atom, a haloalkoxy group having 1 to 4 carbon atoms, and a phenyl ring, each independently a halogen atom, an alkyl group having 1 to 4 carbon atoms, 1 to 4 May be substituted with 5 or less substituents selected from a haloalkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and a haloalkoxy group having 1 to 4 carbon atoms. A phenyl ring, a cycloalkyl group having 3 to 8 carbon atoms, a halocycloalkyl group having 3 to 8 carbon atoms, wherein at least one R d is an optionally substituted phenyl ring Select from Be is the aromatic ring； R a is hydrogen, alkyl having 1-4 haloalkyl group an
